Literature DB >> 3757406

Disposition of vancomycin during hemofiltration.

G R Matzke, M B O'Connell, A J Collins, P R Keshaviah.   

Abstract

The disposition of vancomycin was assessed in five patients receiving hemofiltration after intravenous dosing with an 18 mg/kg dose after a hemofiltration procedure. The serum concentration-time profile was characterized before, during, and after the next hemofiltration procedure. The t 1/2 of vancomycin was 136.0 +/- 27.2 hours (mean +/- SD) before hemofiltration and 4.1 +/- 1.2 during hemofiltration. Approximately 400 mg of vancomycin was recovered in the filtrate and the hemofiltration clearance was 152.6 +/- 21.5 ml/min. A significant relationship was observed between vancomycin clearance and ultrafiltration flow rate (r = 0.9914). A marked rebound in vancomycin serum concentration (52.4% +/- 15.6%) was observed in all patients. Hemofiltration has a significant effect on the disposition of vancomycin. Because of the marked interpatient variability in elimination t 1/2 and the degree and time course of the rebound, an individualized approach to vancomycin therapy in this patient population is recommended.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3757406     DOI: 10.1038/clpt.1986.201

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Elimination of vancomycin during hemofiltration.

Authors:  P Rawer; K E Seim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

2.  Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing.

Authors:  Catherine S C Bouman; Hendrikus J M van Kan; Richard P Koopmans; Johanna C Korevaar; Marcus J Schultz; Margreeth B Vroom
Journal:  Intensive Care Med       Date:  2006-10-17       Impact factor: 17.440

3.  Kinetics of ceftazidime during plasmapheresis.

Authors:  F Bozkurt; P Schollmeyer; E Keller
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

5.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

6.  Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration.

Authors:  J M Kinowski; J E de la Coussaye; F Bressolle; D Fabre; G Saissi; O Bouvet; M Galtier; J J Eledjam
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Pharmacokinetics of vancomycin during continuous hemodiafiltration.

Authors:  C Santré; O Leroy; M Simon; H Georges; B Guery; C Beuscart; G Beaucaire
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Effect of orally administered activated charcoal on vancomycin clearance.

Authors:  R L Davis; R A Roon; J R Koup; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

9.  Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition.

Authors:  K J Klamerus; K A Rodvold; N A Silverman; S Levitsky
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.